Keyphrases
Triple-negative Breast Cancer
100%
Glycoprotein
100%
Dynamic PET
100%
Antibody-based
100%
Diagnostic Agents
100%
Companion Diagnostics
100%
GPNMB
100%
Zirconium-89 (89Zr)
87%
CDX-011
37%
Xenograft
25%
Tumor Uptake
25%
MDA-MB-468
25%
Diagnostic Imaging Agents
25%
Tumor
12%
Immunoreactivity
12%
Breast Cancer Cell Lines
12%
Triple-negative Breast Cancer Cells
12%
Patient-derived Xenograft
12%
Metastasis
12%
Protein Expression
12%
High Affinity
12%
PET Study
12%
Radiation Dosimetry
12%
Expression Level
12%
Human Use
12%
Patient Selection
12%
Targeted Treatment
12%
Antibody-drug Conjugate
12%
Cellular Uptake
12%
Targets for Therapy
12%
Effective Dose
12%
PET-based
12%
Biodistribution Studies
12%
Brentuximab Vedotin
12%
Pharmacological Properties
12%
Emerging Biomarkers
12%
MDA-MB-231
12%
Optimal Imaging
12%
Medicine and Dentistry
Positron Emission Tomography
100%
Triple Negative Breast Cancer
100%
Glycoprotein
100%
Metastatic Melanoma
100%
Diagnostic Agent
100%
Glembatumumab
88%
Zirconium 89
77%
Glembatumumab Vedotin
44%
Neoplasm
33%
Xenograft
33%
Imaging Agent
22%
Diagnostic Imaging
22%
Polyethylene Terephthalate
22%
Biological Marker
11%
Metastatic Carcinoma
11%
Targeted Therapy
11%
Immunoreactivity
11%
Protein Expression
11%
Enzyme Linked Immunosorbent Assay
11%
Recurrent Disease
11%
Antibody-Drug Conjugate
11%
Dosimetry
11%
Breast Cancer Cell Line
11%
Biodistribution
11%
Pharmacology, Toxicology and Pharmaceutical Science
Triple Negative Breast Cancer
100%
Glycoprotein
100%
Diagnostic Agent
100%
Metastatic Melanoma
100%
Polyethylene Terephthalate
100%
Glembatumumab
88%
Zirconium 89
77%
Glembatumumab Vedotin
44%
Neoplasm
33%
Biological Marker
11%
Recurrent Disease
11%
Dosimetry
11%
Biodistribution
11%
Preclinical Study
11%
Enzyme-Linked Immunosorbent Assay
11%
Antibody Drug Conjugate
11%
Immunology and Microbiology
Positron Emission Tomography
100%
Glycoprotein
100%
Glembatumumab
88%
Glembatumumab Vedotin
44%
Xenograft
33%
Protein Expression
11%
Immunoreactivity
11%
Preclinical Study
11%
ELISA
11%
Antibody Drug Conjugate
11%
Breast Cancer Cell Line
11%